Yue Xiangyue Health Not Filed for IPO as of June 2026
Barty Medical
Vascular Interventional and Implantable Device R&D Manufacturer
Vivolight
Developer of Biomedical Optical Imaging Systems
Highlightll Pharma
Innovative Drug Developer
Trinomab
Developer of Natural Fully Human Monoclonal Antibody New Drugs
SPH
Pharmaceutical R&D and Manufacturing
Atom Therapeutics
Innovative Drug Developer
Click to Follow? | Focused on Global Biopharma Investment
On June 10, 2026, "Shenzhen Yifeng Mingyuan Seed Venture Capital Partnership (Limited Partnership)," established with equity participation from the Shenzhen Science and Technology Innovation Seed Fund, officially completed its industrial and commercial registration, marking a critical step forward in Yifeng Capital’s strategic layout for ultra-early-stage investments.
Notably, the portfolio ecosystem of Yifeng Capital has seen a surge of positive developments this month, with multiple investee companies achieving breakthroughs in advancing financing rounds and expanding core businesses. The overall investment ecosystem is accelerating into a phase of tangible outcome realization.
Westlake Biology
· Xihu Biology Completes Over RMB 100 Million in Financing
Westlake Biosciences Announces Completion of New Strategic Financing Round Exceeding RMB 100 Million; Yifeng Capital, as an Existing Shareholder, Continues to Increase Investment
Carbon: The Origin of All Life
· Tansheng Wanwu Completes Series A Financing
Carbon Genesis Completes Series A FinancingRecently, Carbon Genesis completed its Series A financing round. The round was invested by institutions including Yifeng Capital and Boyuan Capital.
Barty Medical
· Barty Medical Completes Nearly RMB 200 Million in Series D Financing
Recently, Barty Medical completed a Series D financing round of nearly RMB 200 million, accelerating the commercialization and globalization of its innovative pan-vascular interventional devices.
Ruijiakang
· Ruijiakang Secures Additional Funding
Recently, Wuhan Ruijiakang secured Series B financing from Yifeng Zhuohua Fund. The funds raised in this round will be primarily used for the "Demonstration Base for Non-Grain Biological Manufacturing of 10,000-Ton-Level Bio-Based Platform Compounds" project.
Vivolight
· Completed hundreds of millions in financing
Vivolight Completes New Round of Financing Worth Hundreds of Millions of YuanRecently, Vivolight completed a new round of financing amounting to hundreds of millions of yuan. This round was co-led by China-US Green Yangtze River Delta Fund and Yifeng Capital.
Highlightll Pharma
· Highlightll Pharma Files for HK IPO
On June 8, the HKEX website showed that Highlightll Pharma submitted an IPO application.
Westlake Biology
· Xihu Biology Completes Over RMB 100 Million in Financing
Westlake Biology
· Xihu Biology Completes Over RMB 100 Million in Financing
Westlake Biosciences Announces Completion of New Strategic Financing Round Exceeding RMB 100 Million; Yifeng Capital, as an Existing Shareholder, Continues to Increase Investment
Carbon: The Origin of All Life
· Tansheng Wanwu Completes Series A Financing
Carbon: The Origin of All Life
· Tansheng Wanwu Completes Series A Financing
Carbon Genesis Completes Series A FinancingRecently, Carbon Genesis completed its Series A financing round. The round was invested by institutions including Yifeng Capital and Boyuan Capital.
Barty Medical
· Barty Medical Completes Nearly RMB 200 Million in Series D Financing
Barty Medical
· Barty Medical Completes Nearly RMB 200 Million in Series D Financing
Recently, Barty Medical completed a Series D financing round of nearly RMB 200 million, accelerating the commercialization and globalization of its innovative pan-vascular interventional devices.
Ruijiakang
· Ruijiakang Secures Additional Funding
Ruijiakang
· Ruijiakang Secures Additional Funding
Recently, Wuhan Ruijiakang secured Series B financing from Yifeng Zhuohua Fund. The funds raised in this round will be primarily used for the "Demonstration Base for Non-Grain Biological Manufacturing of 10,000-Ton-Level Bio-Based Platform Compounds" project.
Vivolight
· Completed hundreds of millions in financing
Vivolight
· Completed hundreds of millions in financing
Vivolight Completes New Round of Financing Worth Hundreds of Millions of YuanRecently, Vivolight completed a new round of financing amounting to hundreds of millions of yuan. This round was co-led by China-US Green Yangtze River Delta Fund and Yifeng Capital.
Highlightll Pharma
· Highlightll Pharma Files for HK IPO
Highlightll Pharma
· Highlightll Pharma Files for HK IPO
On June 8, the HKEX website showed that Highlightll Pharma submitted an IPO application.
Highlightll Pharma
· JAK1/TYK2 Proposed for Breakthrough Therapy Designation
Highlightll Pharma
· JAK1/TYK2 Proposed for Breakthrough Therapy Designation
Highlightll Pharma
· JAK1/TYK2 Proposed for Breakthrough Therapy Designation
On June 24, 2026, Highlightll Pharma’s JAK1/TYK2 inhibitor TLL-018 tablets were proposed for inclusion in the Breakthrough Therapy Designation program for the treatment of rheumatoid arthritis.
Trinomab
· Partnering with SPH to Accelerate the Global Rollout of the Next-Generation “Tetanus Shot,” Stedumab
Trinomab
· Partnering with SPH to Accelerate the Global Rollout of the Next-Generation “Tetanus Shot,” Stedumab
Recently, Trinomab and the International Business Division of SPH held a signing ceremony in Shanghai for the strategic commercialization partnership of Stalidumab in the Philippines.
Huayuan Regeneration
· Attending ISO 2026: Discussing Frontier Explorations in the Treatment of Kidney Diseases
Huayuan Regeneration
· Attending ISO 2026: Discussing Frontier Explorations in the Treatment of Kidney Diseases
June 11–12, ISO 2026 Fifth In-Depth Focus Forum on Stem Cell Therapy and Organoids Held in Beijing.Dr. Liu Yajing, Vice President of R&D for Regenerative Cells at Huayuan, was deeply involved in the sub-forum on “Development of iPSC-Derived Stem Cell Therapies.”
KENTUO Fluid
· The New MAP96 Pipette Has Arrived
June 11–12, ISO 2026 Fifth In-Depth Focus Forum on Stem Cell Therapy and Organoids Held in Beijing.Dr. Liu Yajing, Vice President of R&D for Regenerative Cells at Huayuan, was deeply involved in the sub-forum on “Development of iPSC-Derived Stem Cell Therapies.”
June 11–12, ISO 2026 Fifth In-Depth Focus Forum on Stem Cell Therapy and Organoids Held in Beijing.Dr. Liu Yajing, Vice President of R&D for Regenerative Cells at Huayuan, was deeply involved in the sub-forum on “Development of iPSC-Derived Stem Cell Therapies.”
KENTUO Fluid
· The New MAP96 Pipette Has Arrived
KENTUO Fluid
· The New MAP96 Pipette Has Arrived
Recently, the new version of Kentuo's MAP96 pipette has been launched.
Atom Therapeutics
· New Anti-Gout Drug Launches Phase III Clinical Trials in China
Atom Therapeutics
· New Anti-Gout Drug Launches Phase III Clinical Trials in China
Atom Therapeutics
· New Anti-Gout Drug Launches Phase III Clinical Trials in China
Atom Therapeutics
· New Anti-Gout Drug Launches Phase III Clinical Trials in China
On June 23, Atom Therapeutics announced that its independently developed innovative small-molecule drug for gout, ABP-671 (lingdolinurad), has initiated Phase III clinical trials in China, with the first patient enrolled and dosed.
Kening Biotech
· Initiation of the First-in-Human Clinical Trial for Dry Eye Disease
Kening Biotech
· Initiation of the First-in-Human Clinical Trial for Dry Eye Disease
Kening Biotech
· Initiation of the First-in-Human Clinical Trial for Dry Eye Disease
Recently, Kening Biologics announced that the first subject in its first-in-human (FIH) clinical trial for dry eye disease has completed dosing.
Huamei Haolian
· Invited to Attend the AI+ Empowering Alumni Development Forum
Huamei Haolian
· Invited to Attend the AI+ Empowering Alumni Development Forum
Huamei Haolian
· Invited to Attend the AI+ Empowering Alumni Development Forum
Recently, Huamei Haolian was invited to attend the AI+ Empowering Alumni Development Forum, discussing how AI-driven health management is reshaping the value chain of the medical ecosystem.
· Featured at the HKU Business School Forum
On the afternoon of June 13, the themed forum “Smart Innovation in Healthcare, Prosperity and Well-being for the People” was held in Hong Kong. Xu Bingyu, Founder and CEO of Huamei Haolian, attended the event and delivered a keynote speech.
· Featured at the HKU Business School Forum
On the afternoon of June 13, the themed forum “Smart Innovation in Healthcare, Prosperity and Well-being for the People” was held in Hong Kong. Xu Bingyu, Founder and CEO of Huamei Haolian, attended the event and delivered a keynote speech.
Tianqin Biologics
· Tianqin Biologics’ NHP Metabolic Model Debuts at the ADA Annual Meeting
Tianqin Biologics
· Tianqin Biologics’ NHP Metabolic Model Debuts at the ADA Annual Meeting
Tianqin Biologics
· Tianqin Biologics’ NHP Metabolic Model Debuts at the ADA Annual Meeting
Recently, at the 86th Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, USA, Tianqin Bio’s independently developed non-human primate (NHP) models for metabolic diseases attracted widespread attention.
· Supporting the Approval of Mabwell’s Innovative Drug 9MW5211 for Clinical Trials
Recently, Mabwell announced that its innovative drug 9MW5211 had officially received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. Tianqin Xinsheng, a wholly-owned subsidiary of Tianqin Bio, provided comprehensive toxicology research services for this project.
Hanno Medical
· Building a Global ECMO Expert Platform
Hanno Medical
· Building a Global ECMO Expert Platform
From June 11 to 13, the 8th Annual Meeting of the Asia-Pacific Extracorporeal Life Support Organization was held in Japan. Hanuo Medical prominently showcased the multi-configuration conversion capabilities of the Lifemotion ECMO System at the exhibition.
Lingyi Bio
· Debut at the 3rd International GBA1 Conference
Lingyi Bio
· Debut at the 3rd International GBA1 Conference
Recently, Lingyi Biotech made its debut at the 3rd International GBA1 Conference, showcasing the latest advances in gene therapy research for GBA1-associated Parkinson’s disease.
Jingwei Shida
· Debut at the 23rd Beijing International Digestive Disease Forum
Jingwei Shida
· Debut at the 23rd Beijing International Digestive Disease Forum
Jingwei Shida
· Debut at the 23rd Beijing International Digestive Disease Forum
On June 14, the 2026 World Chinese Digestive Physicians Annual Conference and the 23rd Beijing International Digestive Disease Forum concluded in Beijing. Jingwei Shida engaged in discussions with clinical experts on multiple dimensions, including the construction of the WEO-ERCP training system, to jointly explore new pathways for the standardized and precise development of digestive endoscopy.
Zifu Medical
· Debut at the 2026 Hangzhou Endoscopy Conference
On June 4, the 3rd Medical Endoscope Technology Development Conference and the 1st Medical Surgical Robot Forum were held in Hangzhou. Zifu Medical was invited to attend the conference and delivered a keynote presentation.
Zifu Medical
· Debut at the 2026 Hangzhou Endoscopy Conference
On June 4, the 3rd Medical Endoscope Technology Development Conference and the 1st Medical Surgical Robot Forum were held in Hangzhou. Zifu Medical was invited to attend the conference and delivered a keynote presentation.
Real Biotech
· Debut at the ASCO Annual Meeting
Recently, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in the United States. Real Biotech, in collaboration with Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, presented Phase I clinical study data of Azvudine in patients with advanced solid tumors in the form of a poster.
Tiangan Medinno
· Debut at the 2026 BIO International Convention
From June 22 to 25, Tiangang Yinuo made its debut at the 2026 BIO International Convention in the United States, where Dr. Yin Liusong, Chief Scientific Officer, delivered a public presentation.
Pinshan Biotech
· Signed a strategic cooperation agreement with Ripple Gold
Recently, Pinshan Biotech and Ruipuli Jin officially signed a strategic cooperation agreement, announcing deep collaboration in the field of hollow fiber filter products.
Saiyuan Biotech
· Partnering with Walvax Biotechnology to Accelerate the Clinical Development of In Vivo CAR Immune Cell Therapy
Recently, Saiyuan Biotech and Walvax Biotechnology officially signed a project collaboration and development agreement. The two parties will focus on in vivo CAR therapies based on the mRNA-LNP technology platform and jointly advance investigator-initiated trials (IIT) for the treatment of hepatocellular carcinoma solid tumors.
· Featured at the 2026 ASCO Annual Meeting
Recently, the founding team of Saiyuan Bioscience presented two latest research reports on tumor immune cell therapy at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA.
Ailios
· Shining at CPHI China 2026
From June 16 to 18, the 24th World Pharmaceutical Raw Materials China Exhibition was held in Shanghai. Ailios showcased its comprehensive end-to-end filtration solutions, covering depth filtration, liquid pre-filtration, sterilizing-grade filtration, and hardware systems.
Neurate
· Debuted at the Premier Academic Platform in the Asia-Pacific Region
From June 11 to 14, the 20th Asia-Pacific Congress on Cardiovascular and Interventional Radiology was held in Suzhou. NewRay Medical systematically showcased its forward-looking layout and key technological achievements in the field of interventional radiology and nuclear medicine at this conference.
Carbon Gives Rise to All Things
· Construction Begins on Ningdong’s 1,000-Ton e-SAF Project
On June 16, the Carbon Creation 1,000-ton Direct Air Capture (DAC) Project for Sustainable Aviation Fuel (e-SAF) Production Grandly Commenced at the Ningdong Energy and Chemical Industry Base in Ningxia.
BoKang ShiYun
· Global innovative ophthalmic drug CBT-001 completes enrollment of all patients in its international multicenter Phase III clinical trial
Recently, Bokang Shiyun announced that its global innovative ophthalmic drug CBT-001, intended for the treatment of pterygium in its pipeline, has completed the enrollment of all patients at global sites in its international multicenter Phase III clinical trial.
Huiyuan Bio
· On-Site Coverage of the Technology-Enabled Subforum at the Annual Conference of Chinese Hospital Presidents
From June 5 to 7, the 20th Annual Conference of Chinese Hospital Presidents was grandly held at the Xiamen International Expo Center. Heyuan Bio showcased Aofumin® at the “Technology Empowerment” sub-forum.
Huahao Zhongtian
· Debut at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating the core product, Utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelimone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast CancerLatest Data from the FRUTD-001 Study.
Real Biotech
· Debut at the ASCO Annual Meeting
Recently, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in the United States. Real Biotech, in collaboration with Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, presented Phase I clinical study data of Azvudine in patients with advanced solid tumors in the form of a poster.
Real Biotech
· Debut at the ASCO Annual Meeting
Recently, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in the United States. Real Biotech, in collaboration with Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, presented Phase I clinical study data of Azvudine in patients with advanced solid tumors in the form of a poster.
Tiangan Medinno
· Debut at the 2026 BIO International Convention
From June 22 to 25, Tiangang Yinuo made its debut at the 2026 BIO International Convention in the United States, where Dr. Yin Liusong, Chief Scientific Officer, delivered a public presentation.
Tiangan Medinno
· Debut at the 2026 BIO International Convention
From June 22 to 25, Tiangang Yinuo made its debut at the 2026 BIO International Convention in the United States, where Dr. Yin Liusong, Chief Scientific Officer, delivered a public presentation.
Pinshan Biotech
· Signed a strategic cooperation agreement with Ripple Gold
Recently, Pinshan Biotech and Ruipuli Jin officially signed a strategic cooperation agreement, announcing deep collaboration in the field of hollow fiber filter products.
Pinshan Biotech
· Signed a strategic cooperation agreement with Ripple Gold
Recently, Pinshan Biotech and Ruipuli Jin officially signed a strategic cooperation agreement, announcing deep collaboration in the field of hollow fiber filter products.
Saiyuan Biotech
· Partnering with Walvax Biotechnology to Accelerate the Clinical Development of In Vivo CAR Immune Cell Therapy
Recently, Saiyuan Biotech and Walvax Biotechnology officially signed a project collaboration and development agreement. The two parties will focus on in vivo CAR therapies based on the mRNA-LNP technology platform and jointly advance investigator-initiated trials (IIT) for the treatment of hepatocellular carcinoma solid tumors.
· Featured at the 2026 ASCO Annual Meeting
Recently, the founding team of Saiyuan Bioscience presented two latest research reports on tumor immune cell therapy at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA.
Saiyuan Biotech
· Partnering with Walvax Biotechnology to Accelerate the Clinical Development of In Vivo CAR Immune Cell Therapy
Recently, Saiyuan Biotech and Walvax Biotechnology officially signed a project collaboration and development agreement. The two parties will focus on in vivo CAR therapies based on the mRNA-LNP technology platform and jointly advance investigator-initiated trials (IIT) for the treatment of hepatocellular carcinoma solid tumors.
· Featured at the 2026 ASCO Annual Meeting
Recently, the founding team of Saiyuan Bioscience presented two latest research reports on tumor immune cell therapy at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA.
Ailios
· Shining at CPHI China 2026
From June 16 to 18, the 24th World Pharmaceutical Raw Materials China Exhibition was held in Shanghai. Ailios showcased its comprehensive end-to-end filtration solutions, covering depth filtration, liquid pre-filtration, sterilizing-grade filtration, and hardware systems.
Ailios
· Shining at CPHI China 2026
From June 16 to 18, the 24th World Pharmaceutical Raw Materials China Exhibition was held in Shanghai. Ailios showcased its comprehensive end-to-end filtration solutions, covering depth filtration, liquid pre-filtration, sterilizing-grade filtration, and hardware systems.
Neurate
· Debuted at the Premier Academic Platform in the Asia-Pacific Region
From June 11 to 14, the 20th Asia-Pacific Congress on Cardiovascular and Interventional Radiology was held in Suzhou. NewRay Medical systematically showcased its forward-looking layout and key technological achievements in the field of interventional radiology and nuclear medicine at this conference.
Neurate
· Debuted at the Premier Academic Platform in the Asia-Pacific Region
From June 11 to 14, the 20th Asia-Pacific Congress on Cardiovascular and Interventional Radiology was held in Suzhou. NewRay Medical systematically showcased its forward-looking layout and key technological achievements in the field of interventional radiology and nuclear medicine at this conference.
Carbon Gives Rise to All Things
· Construction Begins on Ningdong’s 1,000-Ton e-SAF Project
On June 16, the Carbon Creation 1,000-ton Direct Air Capture (DAC) Project for Sustainable Aviation Fuel (e-SAF) Production Grandly Commenced at the Ningdong Energy and Chemical Industry Base in Ningxia.
BoKang ShiYun
· Global innovative ophthalmic drug CBT-001 completes enrollment of all patients in its international multicenter Phase III clinical trial
Recently, Bokang Shiyun announced that its global innovative ophthalmic drug CBT-001, intended for the treatment of pterygium in its pipeline, has completed the enrollment of all patients at global sites in its international multicenter Phase III clinical trial.
Carbon Gives Rise to All Things
· Construction Begins on Ningdong’s 1,000-Ton e-SAF Project
On June 16, the Carbon Creation 1,000-ton Direct Air Capture (DAC) Project for Sustainable Aviation Fuel (e-SAF) Production Grandly Commenced at the Ningdong Energy and Chemical Industry Base in Ningxia.
BoKang ShiYun
· Global innovative ophthalmic drug CBT-001 completes enrollment of all patients in its international multicenter Phase III clinical trial
Recently, Bokang Shiyun announced that its global innovative ophthalmic drug CBT-001, intended for the treatment of pterygium in its pipeline, has completed the enrollment of all patients at global sites in its international multicenter Phase III clinical trial.
Huiyuan Bio
· On-Site Coverage of the Technology-Enabled Subforum at the Annual Conference of Chinese Hospital Presidents
Huiyuan Bio
· On-Site Coverage of the Technology-Enabled Subforum at the Annual Conference of Chinese Hospital Presidents
Huiyuan Bio
· On-Site Coverage of the Technology-Enabled Subforum at the Annual Conference of Chinese Hospital Presidents
From June 5 to 7, the 20th Annual Conference of Chinese Hospital Presidents was grandly held at the Xiamen International Expo Center. Heyuan Bio showcased Aofumin® at the “Technology Empowerment” sub-forum.
Huahao Zhongtian
· Debut at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating the core product, Utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelimone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast CancerLatest Data from the FRUTD-001 Study.
Huahao Zhongtian
· Debut at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating the core product, Utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelimone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast CancerLatest Data from the FRUTD-001 Study.
Huahao Zhongtian
· Debut at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating the core product, Utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelimone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast CancerLatest Data from the FRUTD-001 Study.
Huahao Zhongtian
· Debut at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating the core product, Utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelimone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast CancerLatest Data from the FRUTD-001 Study.
Pulai Pharma
· World's First Ganan-Class Antimicrobial Peptide Drug Approved for Market Launch
On June 17, Puyi Pharmaceutical’s independently developed Puyike®, China’s first Class 1 innovative drug featuring garenin-class antimicrobial peptides, received marketing approval from the National Medical Products Administration (NMPA).
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, the “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit,” independently developed by Ruijing Biotechnology, received the Class III Medical Device Registration Certificate issued by the National Medical Products Administration. It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, UTD2 (utidelone capsules), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Vivolight
· Domestically Developed 355nm Cold Laser Ablation Device Approved for Market Launch
Recently, the FastErazer triple-frequency Nd:YAG laser ablation device, independently developed by Vivolight’s subsidiary Zhongke Rongguang, has officially received approval from the National Medical Products Administration for market launch.
Tingsheng Technology
· No.7AmountICEProductTINGSN Sonic Eyes 8 Pro Approved
On June 23, Tingsn Technology’s TINGSN Sonic Eyes 8 Pro single-use intracardiac echocardiography diagnostic catheter officially received approval from the National Medical Products Administration (NMPA), successfully obtaining a Class III medical device registration certificate.
Xuanyu Medical
· StrenSoft™ Adjustable-Curved Pulmonary Artery Embolectomy Stent System Officially ApprovedNMPA
On June 1, the StrenSoft™ Adjustable-Curve Pulmonary Artery Embolectomy Stent System, independently developed by Xuanyu Medical, officially received market approval from the National Medical Products Administration (NMPA).
Trunol Bio
· New Drug Application for Iqirunlencel Injection Officially Approved by Singapore’s Health Sciences Authority
On June 18, Gracell Biotechnologies announced that the Health Sciences Authority (HSA) of Singapore had formally approved its new drug application for marketing authorization of Iciloleucel Injection, a fully human anti-BCMA CAR-T cell therapy product independently developed by the company.
Pulai Pharma
· World's First Ganan-Class Antimicrobial Peptide Drug Approved for Market Launch
On June 17, Puyi Pharmaceutical’s independently developed Puyike®, China’s first Class 1 innovative drug featuring garenin-class antimicrobial peptides, received marketing approval from the National Medical Products Administration (NMPA).
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, the “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit,” independently developed by Ruijing Biotechnology, received the Class III Medical Device Registration Certificate issued by the National Medical Products Administration. It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, UTD2 (utidelone capsules), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Vivolight
· Domestically Developed 355nm Cold Laser Ablation Device Approved for Market Launch
Recently, the FastErazer triple-frequency Nd:YAG laser ablation device, independently developed by Vivolight’s subsidiary Zhongke Rongguang, has officially received approval from the National Medical Products Administration for market launch.
Tingsheng Technology
· No.7AmountICEProductTINGSN Sonic Eyes 8 Pro Approved
On June 23, Tingsn Technology’s TINGSN Sonic Eyes 8 Pro single-use intracardiac echocardiography diagnostic catheter officially received approval from the National Medical Products Administration (NMPA), successfully obtaining a Class III medical device registration certificate.
Xuanyu Medical
· StrenSoft™ Adjustable-Curved Pulmonary Artery Embolectomy Stent System Officially ApprovedNMPA
On June 1, the StrenSoft™ Adjustable-Curve Pulmonary Artery Embolectomy Stent System, independently developed by Xuanyu Medical, officially received market approval from the National Medical Products Administration (NMPA).
Trunol Bio
· New Drug Application for Iqirunlencel Injection Officially Approved by Singapore’s Health Sciences Authority
On June 18, Gracell Biotechnologies announced that the Health Sciences Authority (HSA) of Singapore had formally approved its new drug application for marketing authorization of Iciloleucel Injection, a fully human anti-BCMA CAR-T cell therapy product independently developed by the company.
Pulai Pharma
· World's First Ganan-Class Antimicrobial Peptide Drug Approved for Market Launch
On June 17, Puyi Pharmaceutical’s independently developed Puyike®, China’s first Class 1 innovative drug featuring garenin-class antimicrobial peptides, received marketing approval from the National Medical Products Administration (NMPA).
Pulai Pharma
· World's First Ganan-Class Antimicrobial Peptide Drug Approved for Market Launch
On June 17, Puyi Pharmaceutical’s independently developed Puyike®, China’s first Class 1 innovative drug featuring garenin-class antimicrobial peptides, received marketing approval from the National Medical Products Administration (NMPA).
Pulai Pharma
· World's First Ganan-Class Antimicrobial Peptide Drug Approved for Market Launch
On June 17, Puyi Pharmaceutical’s independently developed Puyike®, China’s first Class 1 innovative drug featuring garenin-class antimicrobial peptides, received marketing approval from the National Medical Products Administration (NMPA).
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, the “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit,” independently developed by Ruijing Biotechnology, received the Class III Medical Device Registration Certificate issued by the National Medical Products Administration. It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, UTD2 (utidelone capsules), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, the “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit,” independently developed by Ruijing Biotechnology, received the Class III Medical Device Registration Certificate issued by the National Medical Products Administration. It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, UTD2 (utidelone capsules), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, the “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit,” independently developed by Ruijing Biotechnology, received the Class III Medical Device Registration Certificate issued by the National Medical Products Administration. It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, UTD2 (utidelone capsules), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Vivolight
· Domestically Developed 355nm Cold Laser Ablation Device Approved for Market Launch
Recently, the FastErazer triple-frequency Nd:YAG laser ablation device, independently developed by Vivolight’s subsidiary Zhongke Rongguang, has officially received approval from the National Medical Products Administration for market launch.
Tingsheng Technology
· No.7AmountICEProductTINGSN Sonic Eyes 8 Pro Approved
On June 23, Tingsn Technology’s TINGSN Sonic Eyes 8 Pro single-use intracardiac echocardiography diagnostic catheter officially received approval from the National Medical Products Administration (NMPA), successfully obtaining a Class III medical device registration certificate.
Xuanyu Medical
· StrenSoft™ Adjustable-Curved Pulmonary Artery Embolectomy Stent System Officially ApprovedNMPA
On June 1, the StrenSoft™ Adjustable-Curve Pulmonary Artery Embolectomy Stent System, independently developed by Xuanyu Medical, officially received market approval from the National Medical Products Administration (NMPA).
Trunol Bio
· New Drug Application for Iqirunlencel Injection Officially Approved by Singapore’s Health Sciences Authority
On June 18, Gracell Biotechnologies announced that the Health Sciences Authority (HSA) of Singapore had formally approved its new drug application for marketing authorization of Iciloleucel Injection, a fully human anti-BCMA CAR-T cell therapy product independently developed by the company.
Approved to Establish a Branch Station for Postdoctoral Research
Won the 2026 Global MedTech "Ophthalmology Innovative Device Award"
· Century Kangtai
Achieved a Perfect Score in the National Health Commission’s Clinical Laboratory Center (NCCL) – 2026 Pilot Proficiency Testing Program for High-Throughput Sequencing Detection of Solid Tumor Fusion Genes (RNA Level)
· Majing Genomics
Molecular Lab Wins the “Jiutian Lanyue Award” at the 2026 Insurance Technology Innovation Competition
· Huamei Haolian
Ranked Among E-Drug Manager’s 2026 Top 100 Innovative Pharmaceutical Enterprises in China
· Ascentage Pharma, Tiangang Yino
Recognized as a Hangzhou “Good Seedling” Enterprise
· Westlake Omics
Appointed as Head of the Artificial Intelligence Department of the 4th Executive Committee of CCI
· Zhu Rui, Chairman of Vivolight
Honored as One of the Top 100 in Chemical Drug R&D Strength in 2026
· Betta Pharmaceuticals
Honored as One of the Top 100 Seed Enterprises in China's Pharmaceutical Innovation for 2026
· Highlightll Pharma
Approved to Establish a Branch Station for Postdoctoral Research
Won the 2026 Global MedTech "Ophthalmology Innovative Device Award"
· Century Kangtai
Achieved a Perfect Score in the National Health Commission’s Clinical Laboratory Center (NCCL) – 2026 Pilot Proficiency Testing Program for High-Throughput Sequencing Detection of Solid Tumor Fusion Genes (RNA Level)
· Majing Genomics
Molecular Lab Wins the “Jiutian Lanyue Award” at the 2026 Insurance Technology Innovation Competition
· Huamei Haolian
Ranked Among E-Drug Manager’s 2026 Top 100 Innovative Pharmaceutical Enterprises in China
· Ascentage Pharma, Tiangang Yino
Recognized as a Hangzhou “Good Seedling” Enterprise
· Westlake Omics
Appointed as Head of the Artificial Intelligence Department of the 4th Executive Committee of CCI
· Zhu Rui, Chairman of Vivolight
Honored as One of the Top 100 in Chemical Drug R&D Strength in 2026
· Betta Pharmaceuticals
Honored as One of the Top 100 Seed Enterprises in China's Pharmaceutical Innovation for 2026
· Highlightll Pharma
Yifeng Capital
China's Venture Capital Firms in the Equity Investment Industry
Zhu Pai, CEO of Yifeng Capital
2026 China's Best Young Investment Figures
Yifeng Mingyuan Seed Fund Lands in Guangming
· On June 10, Shenzhen Yifeng Mingyuan Seed Venture Capital Partnership (Limited Partnership), established with participation from the Shenzhen Science and Technology Innovation Seed Fund, officially completed its industrial and commercial registration. This marks a critical step forward in Yifeng Capital’s strategic layout for ultra-early-stage investments.
Multiple Portfolio Companies of Yifeng Capital Present Breakthrough Data at ASCO 2026
·June 2, AnnualThe Annual Meeting of the American Society of Clinical Oncology (ASCO), a premier global academic conference in the field of oncology, has concluded in the United States. Portfolio companies of Yifeng Capital—Westlake Biopharmaceuticals, Zhen Shi Bio, Qiyu Biologics, Huahao Zhongtian, Saiyuan Biotechnology, Ascentage Pharma, and Chipscreen Biosciences—presented significant clinical research findings.
✦
Recommended Reading
✦
Northin Life's IPO on the STAR Market
✦
Recommended Reading
✦
Northin Life's IPO on the STAR Market
Northin Life's IPO on the STAR Market
Wuhan Healthgen Biotech's IPO on the STAR Market
BoKang ShiYun's IPO on the Main Board of the Hong Kong Stock Exchange
Shenghe Biotech Hong Kong Main Board IPO
Quanxin Biotech Hong Kong Main Board IPO
"Against the Current, Advancing with Time"
3D Medicines Hong Kong Main Board IPO
GeneChem's IPO on the STAR Market
Ten Years Sharpening the Sword, Unsheathed with Razor Edge
Yahong Medicine's IPO on the STAR Market
Looking forward to your
Share
Like
Watching
Wuhan Healthgen Biotech's IPO on the STAR Market
Wuhan Healthgen Biotech's IPO on the STAR Market
Wuhan Healthgen Biotech's IPO on the STAR Market
BoKang ShiYun's IPO on the Main Board of the Hong Kong Stock Exchange
BoKang ShiYun's IPO on the Main Board of the Hong Kong Stock Exchange
Shenghe Biotech Hong Kong Main Board IPO
Quanxin Biotech Hong Kong Main Board IPO
"Against the Current, Advancing with Time"
3D Medicines Hong Kong Main Board IPO
GeneChem's IPO on the STAR Market
Ten Years Sharpening the Sword, Unsheathed with Razor Edge
Yahong Medicine's IPO on the STAR Market
Looking forward to your
Share
Like
Watching